The Dementia Discovery Fund (DDF) is a venture capital fund, delivering both high-impact therapeutics for age related dementias and financial returns by investing in, creating, and supporting innovative companies. I am responsible for helping to build the Fund’s investment portfolio by leading investments in new and established companies, working closely with the Fund’s existing portfolio companies in advisor and director roles, and developing and driving DDF’s investment strategy in collaboration with the leadership team. The DDF is managed by SV Health Investors, a healthcare and life sciences venture capital and growth equity firm.

The Parkinson’s UK Virtual Biotech (VB) programme was established in 2016 as a patient-led programme to discover and develop new treatments for Parkinson’s. It represents a core element of the strategy of the Parkinson’s UK charity (the “Charity”) to accelerate breakthroughs in research. Parkinson's Research Ventures (PRV) is a wholly-owned subsidiary of the Charity and was established in 2018 as a vehicle through which many of the financing and IP transactions for the VB Programme would be pursued. I am a volunteer independent director on the board of PRV.

Director, Chair of the Transaction Committee, member of the Compensation Committee. Merck (NYSE: MRK) acquired Caraway Therapeutics for a total potential consideration of up to $610 million.

The JDRF T1D Fund (www.t1dfund.org) is a venture philanthropy fund accelerating life-changing solutions to treat, prevent and cure type 1 diabetes (T1D) through catalytic commercial investments. Through its investments in partnership with private capital, including venture capital, corporations and foundations, the T1D Fund seeks to attract the private investment necessary to advance drugs, devices, diagnostics, and vaccines into the hands of those living with T1D. The T1D Fund invests in areas strategically aligned with JDRF, the leading global organization funding T1D research, with an exclusive focus on supporting the best commercial opportunities. The T1D Fund will reinvest any realized gains into new investments to further its mission.

Executive Director level manager responsible for shaping and executing mission-driven Partners HealthCare Innovation (http://innovation.partners.org/) based commercial offerings and strategy in key priority areas or market sectors. I lead and manage 9 licensing professionals organized into market sector teams, focused on creating commercial strategies and new opportunities from the overlap of industry interests and Partners assets. I am accountable for engaging top level industry executives, senior investors, clinical leaders, and innovators to design, grow and manage these high value, high impact industrial relationships.

Using the power of immunology to develop new treatments for cancer, fibrosis and autoimmunity. Acquired by MRK in 2019.

Entrega makes injectable substances available orally. As co-founder and COO of Entrega I closed a multi-million dollar R&D collaboration with Google[x], led the licensing negotiations and transaction, was responsible for long-term strategy and day-to-day operations, and managed multiple R&D alliances with major pharmaceutical companies. http://www.entregabio.com/

Vedanta is developing a novel class of therapies that modulate pathways of interaction between the human microbiome and the host immune system. As a co-founder, sourced and licensed technologies, assembled Scientific Advisory Boards, created IP and IP strategy, and secured funding from PureTech for microbiome related initiatives.

Mandara was founded by PureTech and a team of experts in the food and nutrition industry to deliver health through nutrition. As a co-founder, I collaborated in crafting the initial company strategy and in raising funding from a major corporate partner. http://www.mandarasciences.com/

Tal is developing breakthrough neuromodulation treatment for psychiatric disorders. As a co-founder, I sourced and evaluated technologies, led the licensing negotiations and transaction, and created IP and long-term strategy. http://www.talmedical.com/

I led and participated on teams identifying, evaluating, creating, operating, and partnering life science investment opportunities and start-up companies with major pharmaceutical companies. Enlight is a Boston-based company established in partnership with major pharmaceutical companies (MRK, PFE, LLY, JNJ, ABT, AZN, NVO) to develop breakthrough innovations that will fundamentally alter drug discovery and development. Funded and guided by these pharmaceutical companies, Enlight proactively addresses critical unmet industry needs with innovations drawn from academic laboratories, startups, and ideas generated internally by the Enlight team. Prior to joining Enlight I was heavily involved in the foundation and expansion of the Enlight partnership. Within Enlight, I was responsible for search, evaluation, and internal and external relationship management resulting in multiple option or license agreements for our portfolio companies. Within these companies I held multiple operational roles. I began as Senior Director of Technology and Business Development in 2011.

As a Principal at PureTech Ventures (now PureTech Health, http://puretechhealth.com/, LON:PRTC) I led the creative conceptualization, technology identification, diligence, in-licensing, and business development activities necessary to create and fund innovative biotechnology companies. I was a founding team member of >5 companies including Enlight, Endra, Vedanta, Mandara, and Tal Medical. My responsibilities also included internal and external communications and relationship management, IP strategy and creation, scientific and corporate strategy, deal making and licensing, and operation of start-up companies. I began at PureTech in 2006, became an associate in 2007, and a Sr. Associate in 2009.

Endra, Inc. (NASDAQ:NDRAU) is commercializing a breakthrough medical imaging technology that combines the properties of light-based (optical) imaging with ultrasound, based on the principles of photoacoustics. As a co-founder, I sourced and licensed technologies, assembled scientific advisers, managed academic collaborations, and created IP and company strategy.

Venture backed company which raised >$15M to develop innovative treatments for pain.